Cardiac Prosthetic Devices Market Size & Share 2026-2035

Cardiac Prosthetic Devices Market Size 

The global cardiac prosthetic devices market was valued at USD 14.6 billion in 2025. The market is expected to reach USD 15.4 billion in 2026 to USD 25.2 billion in 2035, growing at a CAGR of 5.6% during the forecast period, according to the latest report published by Global Market Insights Inc.

The high market growth is attributed to the increasing prevalence of cardiovascular diseases, growing adoption of minimally invasive procedures, advancements in cardiac device technologies, and rising geriatric population, among other contributing factors. 

Cardiac prosthetic devices are implantable medical devices used to restore or replace the normal function of the heart when it is impaired due to structural or electrical abnormalities. These devices include prosthetic heart valves and pacemakers, which are widely used in the treatment of conditions such as heart valve diseases, arrhythmia, and heart failure. 

The major players in the global cardiac prosthetic devices market include Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences, and BIOTRONIK. These companies maintain their competitive position through continuous product innovation, strong global distribution networks, and significant investments in research and development. 

The market increased from USD 12.8 billion in 2022 to USD 14 billion in 2024, registering a historical growth rate of 4.4%. This growth was primarily driven by the rising incidence of cardiovascular diseases, including heart valve disorders, arrhythmias, and heart failure. Additionally, the increasing adoption of minimally invasive procedures such as transcatheter aortic valve replacement (TAVR), advancements in device materials and design, improved diagnostic and interventional capabilities, and expansion of healthcare infrastructure have supported market expansion. 

Furthermore, the growing global burden of cardiovascular conditions continues to drive demand for cardiac prosthetic devices. Heart valve diseases, particularly aortic stenosis and mitral regurgitation, are more prevalent in elderly populations and often require valve replacement or repair. Similarly, cardiac arrhythmias such as bradycardia necessitate the use of pacemakers to regulate heart rhythm. The increasing aging population, coupled with lifestyle-related risk factors such as hypertension, obesity, and diabetes, is significantly contributing to the rising demand for these devices. 

Cardiac Prosthetic Devices Market Trends 

Several trends are shaping the cardiac prosthetic devices industry. The growing preference for minimally invasive cardiac procedures, such as transcatheter heart valve implantation (TAVI/TAVR) and minimally invasive pacemaker implantation, is significantly driving the adoption of cardiac prosthetic devices. These approaches offer advantages such as reduced procedural risk, shorter hospital stays, and faster recovery compared to open surgical interventions, making them particularly suitable for elderly and high-risk patients. 

• Advancements in prosthetic heart valve materials and design represent another key trend influencing market evolution. The increasing adoption of biological tri-leaflet heart valves is enhancing hemodynamic performance and reducing the need for long-term anticoagulation therapy. In parallel, innovations in valve manufacturing techniques, including advanced welding and material processing methods, are improving durability, structural integrity, and long-term performance. Additionally, growing interest in hybrid prosthetic valves, combining mechanical durability with biocompatibility, is further supporting product innovation and clinical adoption. 

• Additionally, integration of cardiac prosthetic devices with digital health technologies is emerging as a significant trend. Modern pacemakers and cardiac implants are increasingly being integrated with remote monitoring systems and wearable cardiac devices, enabling real-time data transmission on patient condition and device performance to healthcare providers. These connected technologies improve patient management, enable early detection of complications, and support timely clinical intervention, thereby enhancing overall treatment outcomes and contributing to the expanding adoption of advanced cardiac prosthetic devices. 

Cardiac Prosthetic Devices Market Analysis 

Based on product type, the market is classified into heart valves and pacemakers. The heart valves segment has asserted its dominance in the market by securing a significant market share in 2025. The segment is expected to reach USD 15.7 billion by 2035, growing at a CAGR of 6.1% during the forecast period. 

• The rising prevalence of heart valve diseases, particularly aortic stenosis and mitral regurgitation, is a key factor driving the adoption of prosthetic heart valves. These conditions are increasingly observed in the aging population and often require valve replacement or repair interventions, thereby supporting sustained demand for both surgical and transcatheter heart valve solutions. 

• The increasing adoption of minimally invasive procedures, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve replacement (TMVR), is further strengthening segment growth. These techniques offer advantages such as reduced procedural risk, shorter recovery time, and improved patient outcomes compared to conventional open-heart surgery, making them the preferred option for elderly and high-risk patient populations. 

• Ongoing innovation in heart valve design and materials is contributing to segment expansion. Advancements such as bioprosthetic tissue valves with improved durability, anti-calcification technologies, and enhanced hemodynamic performance are increasing device longevity and clinical effectiveness. Additionally, the development of next-generation transcatheter valves with improved deliverability and positioning accuracy is further enhancing adoption rates. 

• The pacemakers segment accounted for USD 5.9 billion in 2025 and is projected to expand at a CAGR of 5% from 2026 to 2035. The segmental growth is driven by the rising prevalence of cardiac arrhythmias, including bradycardia and conduction disorders, along with the increasing aging population that is more susceptible to such conditions. 

Based on end use, the market is classified into hospitals, specialty cardiac centers,  ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 47.8% in 2025. 

• Hospitals represent the primary end user segment in the cardiac prosthetic devices market, as they are equipped with advanced infrastructure and specialized cardiac units required to perform complex procedures such as heart valve replacement surgeries and pacemaker implantation. These procedures rely on high-end imaging systems, catheterization laboratories, and the expertise of cardiac surgeons and electrophysiologists, positioning hospitals as the central point of care for managing cardiovascular conditions, including valve diseases and arrhythmias. 

• Additionally, the expansion of dedicated cardiac care units within hospitals is further supporting the adoption of advanced cardiac prosthetic devices. Hospitals are increasingly focused on improving long-term patient outcomes and cost-effectiveness by utilizing minimally invasive procedures such as transcatheter valve replacements and advanced pacemaker systems. These technologies help reduce hospital readmission rates, shorten recovery periods, and minimize the need for repeat interventions, reinforcing the preference for cardiac prosthetic devices as a standard treatment approach within hospital settings.    

• The specialty cardiac centers segment is anticipated to grow at a CAGR of 6.1% over the forecast period. Growth in this segment is driven by the increasing establishment of dedicated cardiovascular care facilities focused on advanced cardiac diagnostics, interventional cardiology, and complex procedures such as transcatheter heart valve replacements and pacemaker implantation. 

• The ambulatory surgical centers segment is anticipated to grow at a CAGR of 7.5% over the forecast period. Growth in this segment is driven by the increasing shift of minimally invasive cardiac procedures, particularly pacemaker implantation and select catheter-based interventions, to outpatient settings. Improvements in procedural safety, shorter recovery times, and same-day discharge protocols are encouraging the migration of suitable cardiac procedures from hospitals to ASCs. 
   

North America Cardiac Prosthetic Devices Market 

North America dominated the global market with the highest market share of 43.1% in 2025. 

• The U.S. market was valued at USD 2.7 billion and USD 2.8 billion in 2022 and 2023, respectively. The market size reached USD 3 billion in 2025, growing from USD 2.9 billion in 2024, and is anticipated to grow at a CAGR of 4.4% from 2026 to 2035. 

• North America, particularly the U.S., represents a significant market for cardiac prosthetic devices, supported by the high prevalence of cardiovascular diseases. Conditions such as coronary artery disease, heart failure, arrhythmias, and heart valve disorders are widely observed in the region, driven by risk factors including sedentary lifestyles, poor dietary habits, obesity, and hypertension. This substantial disease burden continues to drive demand for cardiac interventions, including heart valve replacement and pacemaker implantation. 

• The region benefits from a well-established healthcare infrastructure and widespread adoption of advanced diagnostic and interventional techniques, including minimally invasive procedures such as transcatheter aortic valve replacement (TAVR) and advanced pacemaker implantation. The availability of highly skilled cardiac surgeons and electrophysiologists supports early diagnosis and effective management of complex cardiovascular conditions, reinforcing strong utilization of cardiac prosthetic devices across hospitals and specialty cardiac centers. 

• Additionally, North America is at the forefront of technological innovation in cardiac care, with continuous advancements in device design and functionality. Developments such as leadless pacemakers, MRI-compatible devices, and next-generation transcatheter heart valves have significantly improved clinical outcomes and expanded the eligible patient population. These technological improvements, combined with strong reimbursement frameworks and early adoption of advanced therapies, position North America as a mature and high-value market for cardiac prosthetic devices. 

Europe Cardiac Prosthetic Devices Market 

Europe market accounted for USD 3.9 billion in 2025 and is anticipated to show lucrative growth over the forecast period. 

• Europe represents a significant and steadily growing market for cardiac prosthetic devices, supported by the rising prevalence of cardiovascular diseases across the region. Conditions such as heart valve disorders, arrhythmias, and heart failure are increasingly observed, particularly in aging populations. In countries such as Germany, there is a strong emphasis on the use of advanced cardiac prosthetic devices, including pacemakers and heart valves, for both curative and palliative management of complex cardiac conditions. 

• Many European countries benefit from well‑established healthcare systems with universal or near‑universal coverage, ensuring broad patient access to advanced cardiac procedures. Hospitals and specialized cardiac centers across the region are equipped with sophisticated infrastructure capable of performing complex surgeries and minimally invasive procedures such as transcatheter heart valve replacement and pacemaker implantation. This availability of advanced facilities and skilled healthcare professionals supports consistent utilization of cardiac prosthetic devices in both acute and chronic cardiac care. 

• Additionally, favorable government policies and reimbursement frameworks across Europe play a crucial role in supporting market growth. In countries such as Germany, cardiac procedures, including pacemaker implantation and heart valve replacement, are covered under mandatory health insurance schemes, reducing financial barriers for patients. 

Asia Pacific Cardiac Prosthetic Devices Market 

The Asia Pacific market is anticipated to grow at the highest CAGR of 6.9% during the analysis timeframe. 

• Asia Pacific represents a rapidly growing market for cardiac prosthetic devices, driven by significant demographic shifts and rising disease prevalence. Countries such as China, which has a rapidly aging population due to increased life expectancy and historical demographic policies, are witnessing a higher incidence of age-related cardiovascular conditions. Elderly populations are more susceptible to conditions such as heart valve diseases, arrhythmias, and conduction disorders, creating strong demand for interventions including pacemaker implantation and heart valve replacement procedures. 

• Healthcare systems in the region are undergoing significant transformation, with countries such as China, Japan, and South Korea investing heavily in expanding and modernizing healthcare infrastructure. The increasing number of hospitals and specialized cardiac centers, particularly in urban areas, is improving access to advanced cardiac care. These facilities are increasingly capable of performing complex cardiac procedures, including minimally invasive interventions and surgical implantations of cardiac prosthetic devices, thereby supporting higher adoption rates across the region. 

• Additionally, the growing capacity of healthcare providers to adopt advanced medical technologies is accelerating the use of next-generation cardiac prosthetic devices. Increasing availability of skilled healthcare professionals, coupled with rising patient awareness and improving affordability in developing economies, is promoting the uptake of minimally invasive procedures and advanced implantable devices. These factors, combined with ongoing healthcare reforms and expanding service capabilities, are positioning Asia Pacific as a high-growth region for cardiac prosthetic devices over the forecast period. 

Latin America Cardiac Prosthetic Devices Market 

The Latin America market is experiencing robust growth over the analysis timeframe. 

• Latin America represents an emerging market for cardiac prosthetic devices, supported by the gradual strengthening of cardiovascular care delivery systems and increasing investment in specialized cardiac services. In countries such as Brazil, Mexico, and Argentina, private healthcare providers are expanding their capabilities in cardiology and cardiac surgery, enabling greater availability of procedures such as pacemaker implantation and heart valve replacement. This expansion in advanced cardiac care services is contributing to rising adoption of cardiac prosthetic devices across the region. 

• Additionally, improvements in referral networks and patient access to tertiary care centers are supporting earlier diagnosis and treatment of cardiovascular conditions requiring prosthetic intervention. The growing collaboration between primary care providers and specialized cardiac centers is enhancing patient pathways for complex procedures, ensuring timely access to device-based treatments, and increasing procedural volumes in urban healthcare settings. 

• Furthermore, increasing participation of global medical device manufacturers in Latin America, through partnerships, distribution expansion, and training initiatives, is improving accessibility and awareness of advanced cardiac prosthetic technologies. As healthcare systems continue to evolve and focus on expanding specialized cardiac care capabilities, the adoption of pacemakers and heart valve devices is expected to grow steadily across the region over the forecast period. 

Middle East & Africa Cardiac Prosthetic Devices Market 

The Middle East & Africa (MEA) market is expected to witness lucrative growth during the forecast period. 

• The Middle East & Africa (MEA) represents a developing market for cardiac prosthetic devices, supported by the increasing burden of cardiovascular risk factors such as obesity, diabetes, and hypertension, particularly in Gulf countries. These conditions significantly contribute to the rising incidence of cardiac complications, including valve dysfunction and rhythm abnormalities, thereby driving the need for interventional treatments involving pacemakers and heart valve prosthetics across the region. 

• Countries in the Gulf Cooperation Council (GCC), including Saudi Arabia, the UAE, and Qatar, are making substantial investments in healthcare modernization, with a strong focus on building centers of excellence in cardiovascular care. The establishment of specialized cardiac institutes and partnerships with international healthcare providers is enhancing clinical capabilities and facilitating the adoption of advanced cardiac prosthetic procedures. 

• Furthermore, increasing government-led healthcare initiatives and public‑private collaborations are improving the availability of advanced cardiac treatments in previously underserved areas. The expansion of medical tourism in countries such as the UAE and Turkey is also contributing to higher procedural volumes, as patients seek high-quality cardiac care involving prosthetic implants. These developments, combined with gradual improvements in healthcare accessibility, are expected to support steady growth of the market across the MEA region. 

Cardiac Prosthetic Devices Market Share 

The global market is characterized by high competition, driven by continuous product innovation, expanding cardiac device portfolios, and a strong focus on improving clinical outcomes in cardiovascular care. Manufacturers are actively investing in the development of advanced cardiac prosthetic devices, including next-generation heart valves and pacemakers, featuring enhanced durability, improved biocompatibility, reduced procedural complexity, and better long-term performance. 

Key players in the market include Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, and BIOTRONIK, which collectively account for approximately ~72% of the total global market share. These companies maintain strong global distribution networks and established relationships with hospitals and cardiac centers. 

In addition to major multinational players, several regional and emerging manufacturers contribute to market competition by offering cost-effective cardiac prosthetic solutions and targeting specific geographic markets. These players focus on expanding access in price-sensitive regions and strengthening their presence through localized manufacturing and distribution strategies. As healthcare infrastructure continues to evolve globally and demand for minimally invasive cardiac interventions increases, competition in the market is expected to intensify, with manufacturers prioritizing technological advancements, clinical evidence generation, and strategic collaborations to strengthen their market positioning. 

Cardiac Prosthetic Devices Market Companies 

A few of the prominent players operating in the cardiac prosthetic devices industry include: 

• Abbott  

• Artivion  

• BIOTRONIK 

• Boston Scientific 

• Colibri Heart Valve 

• CORCYM 

• Edwards Lifesciences 

• Labcor Laboratórios 

• Lepu Medical 

• Medtronic 

• Meril Life Sciences 

• MicroPort  

• Pacetronix 

• Venus Medtech 

• Edwards Lifesciences 

Edwards Lifesciences holds a leading position in the cardiac prosthetic devices market through its strong focus on structural heart innovations, particularly in transcatheter heart valve technologies. The company’s strength lies in its comprehensive portfolio of surgical and transcatheter heart valves, enabling it to address a wide range of valvular heart diseases. 

• Medtronic 

Medtronic is a key player in the cardiac prosthetic devices market, supported by its broad cardiovascular portfolio. The company offers a wide range of pacemakers and transcatheter heart valves designed to address diverse clinical needs. 

• BIOTRONIK 

BIOTRONIK has established a strong presence in the cardiac prosthetic devices market through its specialized focus on pacemakers. The company’s competitive strength lies in its advanced device engineering, including highly reliable implantable pacemakers with long battery life and integrated remote monitoring capabilities. 

Cardiac Prosthetic Devices Industry News: 

• In April 2026, Medtronic plc announced the U.S. launch of its Mosaic Neo mitral bioprosthesis following FDA approval. The next‑generation valve is designed for use in both traditional and minimally invasive cardiac surgeries, including robotic-assisted procedures, offering improved durability, hemodynamics, and ease of implantation. This development strengthens Medtronic’s structural heart portfolio and supports broader adoption of advanced surgical valve solutions. 

• In May 2025, Edwards Lifesciences Corporation received U.S. Food and Drug Administration (FDA) approval for its SAPIEN 3 transcatheter heart valve platform for treating patients with asymptomatic severe aortic stenosis. This expanded indication enables earlier intervention using minimally invasive valve replacement therapy, significantly increasing the eligible patient population and reinforcing Edwards’ leadership in the transcatheter heart valve market. 

• In January 2022, Medtronic plc received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the commercialization of its Micra AV Transcatheter Pacing System (TPS) in Japan. This approval enabled the launch of the leadless pacemaker designed to treat patients with atrioventricular (AV) block using advanced atrial-synchronous pacing technology. The regulatory clearance expanded access to minimally invasive leadless pacing solutions in one of the world’s largest healthcare markets, strengthening Medtronic’s geographic presence and enhancing its competitive positioning. 

The cardiac prosthetic devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type 

• Prosthetic heart valves  

• Mechanical  heart valves  

• Tissue  heart valves  

• Transcatheter  heart valves (TAVR/TMVR)  

• Pacemakers  

• Implantable pacemakers  

• Single-chamber pacemakers 

• Dual-chamber pacemakers 

• Biventricular/CRT pacemakers 

• External pacemakers  

Market, By End Use 

• Hospitals 

• Specialty cardiac centers 

• Ambulatory surgical centers 

• Other end users 

The above information is provided for the following regions and countries: 

• North America

  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE